These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 5942133)

  • 1. [Effect of ethyl alpha-p-chlorophenoxyisobutyrate (Clofibrate) on lipids, cholesterol and uric acid in diabetes mellitus].
    Orsetti A; Mirouze J
    Therapie; 1966; 21(3):685-91. PubMed ID: 5942133
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antilipidemic activity of ethyl-chloro-phenoxy-isobutyrate or clofibrate].
    Barisone D; Gallo G; Accardo S
    Minerva Med; 1969 Jan; 60(6):174-80. PubMed ID: 5776766
    [No Abstract]   [Full Text] [Related]  

  • 3. [The effect of ethyl-chlorophenoxyisobutyrate on the serum lipids in coronary sclerosis].
    Keller L; Rétsági G; Sebestyén M; Diczendy S; Erdélyi G
    Z Gesamte Inn Med; 1966 Mar; 21(6):169-72. PubMed ID: 5988081
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term therapy of adult cases of primary hypertriglyceridaemia with clofibrate (ethyl-p-chlorophenoxyisobutyrate).
    Braunsteiner H; Herbst M; Sandhofer F; Sailer S
    Ger Med Mon; 1968 Feb; 13(2):65-72. PubMed ID: 5653144
    [No Abstract]   [Full Text] [Related]  

  • 5. [Action of ethyl chlorophenoxyisobutyrate (CPIB) on blood lipids].
    Giannini SD; da Silva WN; Luthold WW; Coelho LT; Bitelli T
    Rev Bras Med; 1965 Nov; 22(11):702-7. PubMed ID: 5892979
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypolipidemic effect of chlorophenoxyisobutyrate in adult-onset diabetes mellitus.
    Danowski TS; Novak JF; Saul RW; Vester JW; Moses C
    Clin Pharmacol Ther; 1966; 7(5):631-8. PubMed ID: 5957168
    [No Abstract]   [Full Text] [Related]  

  • 7. Clofibrate and androsterone effect on serum lipids.
    Orgain ES; Bogdonoff MD; Cain C
    Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical contribution to the study of the eulipemic effect of 2 ethyl esters of p-chlorophenoxyisobutyric acid].
    De Michelis S; Paparella P; Seu V
    Clin Ter; 1969 Jul; 50(1):11-26. PubMed ID: 4917326
    [No Abstract]   [Full Text] [Related]  

  • 9. [Action of ethyl chlorophenoxyisobutyrate on several types of hyperlipidemia].
    Beaumont V; Swynghedauw B; Beaumont JL; Himbert J
    Rev Atheroscler (Paris); 1966; 8(1):12-20. PubMed ID: 5961026
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of chlorophenoxy-isobutyric ester on platelet adhesiveness and aggregation in the patients with arteriosclerosis and diabetes mellitus].
    Yasunaga K
    Naika Hokan; 1969 Oct; 16(10):393-403. PubMed ID: 5391800
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hyperlipidemia with the ethyl-ester of chlorophenoxyisobutyrate and androsterone.
    Schatz IJ
    Henry Ford Hosp Med J; 1965 Dec; 13(4):447-56. PubMed ID: 5325188
    [No Abstract]   [Full Text] [Related]  

  • 13. [Influence of beta-benzabutyramide on the blood lipids and on the thrombodensitogram].
    Ferri F; Regazzini A; Pedini G
    G Gerontol; 1970 Mar; 18(3):203-18. PubMed ID: 5473222
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of platelet stickiness tests during an atromid-S trial.
    O'Brien JR; Heywood JB
    Thromb Diath Haemorrh; 1966 Dec; 16(3):768-77. PubMed ID: 5996687
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of clofibrate on serum lipids in atherosclerosis].
    Gietz E
    Med Klin; 1967 Mar; 62(9):336-8 passim. PubMed ID: 5593571
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
    Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-lipaemic effect of Desopimon in obesity and in diabetes mellitus accompanied by obesity.
    Less E
    Ther Hung; 1974; 22(1):27-31. PubMed ID: 4844928
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term treatment of previously therapy-resistant cases of primary hypertriglyceridemia of the adult with ethyl-p-chlorophenoxyisobutyrate].
    Braunsteiner H; Herbst M; Sandhofer F; Sailer S
    Dtsch Med Wochenschr; 1967 Dec; 92(50):2302-8. PubMed ID: 6075896
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus.
    Danowski TS; Cohn RE; Limaye NR; Novak JF; Saul R; Sunder JH; Moses C
    Clin Pharmacol Ther; 1965; 6(6):716-30. PubMed ID: 5321221
    [No Abstract]   [Full Text] [Related]  

  • 20. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.